Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: A systematic review

European Journal of Cancer Prevention

Volumn 24, Issue 2, 2015, Pages 141-149

  Gordon, Louisa G ^a,b   Rowell, David ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Cost of illness; Cost effectiveness; Keratinocyte skin cancer; Melanoma; Screening

Indexed keywords

AUSTRALIA; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; COCHRANE LIBRARY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DENMARK; EARLY DIAGNOSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; MEDLINE; MELANOMA; NEW ZEALAND; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SQUAMOUS CELL CARCINOMA; SWEDEN; SYSTEMATIC REVIEW; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; COST BENEFIT ANALYSIS; ECONOMICS; PRIMARY PREVENTION; QUALITY ADJUSTED LIFE YEAR; SKIN NEOPLASMS;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; HEALTH CARE COSTS; HUMANS; MELANOMA; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; SKIN NEOPLASMS;

EID: 84927691112     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000056     Document Type: Review

References (46)

1. Alexandrescu DT (2009). Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages. Dermatol Online J 15:1.
2. Australian Institute of Health and Welfare (2012). Health expenditure Australia 2010-11. AIHW cat. no. HWE 56. Health and Welfare Expenditure Series No. 47. Canberra: Australian Institute of Health and Welfare.
3. Australian Institute of Health and Welfare (2005). Health system expenditures on cancer and other neoplasms in Australia, 2000-01. AIHW cat. no. HWE 29. Health and Welfare Expenditure Series No. 22. Canberra: Australian Institute of Health and Welfare.
4. Beddingfield FC III (2002). Melanoma: a decision analysis to estimate the effectiveness and cost-effectiveness of screening and an analysis of the relevant epidemiology of the disease. DTIC Document, RAND Graduate School, USA.
5. Bentzen J, Kjellberg J, Thorgaard C, Engholm G, Phillip A, Storm HH (2013). Costs of illness for melanoma and nonmelanoma skin cancer in Denmark. Eur J Cancer Prev 22:569-576.
6. Bilinski KL, Boyages SC (2012). The rising cost of vitamin D testing in Australia: time to establish guidelines for testing. Med J Aust 197:90.
7. Chen JG, Fleischer AB Jr, Smith ED, Kancler C, Goldman ND, Williford PM, Feldman SR (2001). Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg 27:1035-1038.
8. Chevalier J, Bonastre J, Avril MF (2008). The economic burden of melanoma in France: assessing healthcare use in a hospital setting. Melanoma Res 18:40-46.
9. Cristofolini M, Bianchi R, Boi S, Decarli A, Hanau C, Micciolo R, Zumiani G (1993). Analysis of the cost-effectiveness ratio of the health campaign for the early diagnosis of cutaneous melanoma in Trentino, Italy. Cancer 71:370-374.
10. Forsea AM, Del Marmol V, de Vries E, Bailey EE, Geller AC (2012). Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol 167:1124-1130.
11. Fransen M, Karahalios A, Sharma N, English DR, Giles GG, Sinclair RD (2012). Non-melanoma skin cancer in Australia. Med J Aust 197:565-568.
12. Freedberg KA, Geller AC, Miller DR, Lew RA, Koh HK (1999). Screening for malignant melanoma: a cost-effectiveness analysis. J Am Acad Dermatol 41:738-74 5.
13. Garattini L, Cainelli T, Tribbia G, Scopelliti D (1996). Economic evaluation of an educational campaign for early diagnosis of cutaneous melanoma. Pharmacoeconomics 9:146-155.
14. Garbe C, Leiter U (2009). Melanoma epidemiology and trends. Clin Dermatol 27:3-9.
15. Girgis A, Clarke P, Burton RC, Sanson-Fisher RW (1996). Screening for melanoma by primary health care physicians: a cost-effectiveness analysis. J Med Screen 3:47-53.
16. Gordon LG, Scuffham PA, van der Pols JC, McBride P, Williams GM, Green AC (2009). Regular sunscreen use is a cost-effective approach to skin cancer prevention in subtropical settings. J Invest Dermatol 129:2766-2771.
17. Green A, Williams G, Neale R, Hart V, Leslie D, Parsons P, et al. (1999). Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 354:723-729
18. [erratum Lancet 1999;1354:1038].
19. H. Krueger & Associates Inc (2010). The economic burden of skin cancer in Canada: current and projected. British Columbia: Canadian Partnership against Cancer Available at: http://www.cancercare.ns.ca/site-cc/media/can cercare/Economic%20Burden%20of%20Skin%20Cancer%20in% 20Canada%20Report.pdf. pp. 1-204. Available at: http://www.cancercare. ns.ca/site-cc/media/cancercare/Economic%20Burden%20of%20Skin% 20Cancer%20in%20Canada%20Report.pdf.
20. Higashi MK, Veenstra DL, Langley PC (2004). Health economic evaluation of nonmelanoma skin cancer and actinic keratosis. Pharmacoeconomics 22:83-94.
21. Hirst N, Gordon L, Gies P, Green AC (2009). Estimation of avoidable skin cancers and cost-savings to government associated with regulation of the solarium industry in Australia. Health Policy 89:303-311.
22. Hirst NG, Gordon LG, Scuffham PA, Green AC (2012). Lifetime costeffectiveness of skin cancer prevention through promotion of daily sunscreen use. Value Health 15:261-268.
23. Housman TS, Feldman SR, Williford PM, Fleischer AB Jr, Goldman ND, Acostamadiedo JM, Chen GJ (2003). Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 48:425-429.
24. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. CHEERS Task Force (2013). Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care 29:117-122.
25. John Chen G, Yelverton CB, Polisetty SS, Housman TS, Williford PM, Teuschler HV, Feldman SR (2006). Treatment patterns and cost of nonmelanoma skin cancer management. Dermatol Surg 32:1266-1271.
26. Johnston K, Levy AR, Lorigan P, Maio M, Lebbe C, Middleton M, et al. (2012). Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study). Eur J Cancer 48:2175-2182.
27. Kyle JW, Hammitt JK, Lim HW, Geller AC, Hall-Jordan LH, Maibach EW, et al. (2008). Economic evaluation of the US Environmental Protection Agency's SunWise program: sun protection education for young children. Pediatrics 121:e1074-e1084.
28. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. (2009). The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1-e34.
29. Losina E, Walensky RP, Geller A, Beddingfield FC 3rd, Wolf LL, Gilchrest BA, Freedberg KA (2007). Visual screening for malignant melanoma: a costeffectiveness analysis. Arch Dermatol 143:21-28.
30. Maio M, Ascierto P, Testori A, Ridolfi R, Bajetta E, Queirolo P, et al. (2012). The cost of unresectable stage III or stage IV melanoma in Italy. J Exp Clin Cancer Res 31:91.
31. Nilsson GH, Carlsson L, Dal H, Ullén H (2003). Skin diseases caused by ultraviolet radiation: the cost of illness. Int J Technol Assess Health Care 19:724-730.
32. O'dea D (2009). The costs of skin cancer to New Zealand. Wellington: School of Medicine, University of Otago. pp. 1-76. Available at: http://www.cancernz.org.nz/assets/files/info/SunSmart/CostsofSkinCancer-NZ-22October2009. pdf [Accessed 19 December 2013].
33. OECD (2013). What Future for Health Spending? OECD Economics Department Policy Notes, 19 June.
34. PBAC. Public Summary Document: Ipilimumab. Canberra: Department of Health. Available at: http://www.pbs.gov. au/industry/listing/elements/pbac-meetings/psd/2012-11/ipilimumab.pdf [Accessed 19 December 2013].
35. Reyes C, DaCosta Byfield S, Linke R, Satram-Hoang S, Teitelbaum AH (2013). The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs. Melanoma Res 23:159-166.
36. Rogers HW, Coldiron BM (2013). Analysis of skin cancer treatment and costs in the United States Medicare population, 1996-2008. Dermatol Surg 39:35-42.
37. Seidler AM, Pennie ML, Veledar E, Culler SD, Chen SC (2010). Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER) - Medicare data. Arch Dermatol 146:249-256.
38. Shih ST, Carter R, Sinclair C, Mihalopoulos C, Vos T (2009). Economic evaluation of skin cancer prevention in Australia. Prev Med 49:449-453.
39. Souza RJ, Mattedi AP, Rezende ML, Corrêa Mde P, Duarte EM (2009). An estimate of the cost of treating melanoma disease in the state of Sao Paulo - Brazil. An Bras Dermatol 84:237-243.
40. Souza RJ, Mattedi AP, Corrêa MP, Rezende ML, Ferreira AC (2011). An estimate of the cost of treating non-melanoma skin cancer in the state of São Paulo, Brazil. An Bras Dermatol 86:657-662.
41. Stang A, Stausberg J, Boedeker W, Kerek-Bodden H, Jöckel KH (2008). Nationwide hospitalization costs of skin melanoma and non-melanoma skin cancer in Germany. J Eur Acad Dermatol Venereol 22:65-72.
42. Tinghög G, Carlsson P, Synnerstad I, Rosdahl I (2008). Societal cost of skin cancer in Sweden in 2005. Acta Derm Venereol 88:467-473.
43. Tran B, Armstrong BK, Carlin JB, Ebeling PR, English DR, Kimlin MG, et al. (2012). Recruitment and results of a pilot trial of vitamin D supplementation in the general population of Australia. J Clin Endocrinol Metab 97:4473-4480.
44. Tsao H, Rogers GS, Sober AJ (1998). An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol 38:669-680.
45. Vallejo-Torres L, Morris S, Kinge JM, Poirier V, Verne J (2014). Measuring current and future cost of skin cancer in England. J Public Health (Oxf) 36:140-148.
46. Whiteman DC, Whiteman CA, Green AC (2001). Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 12:69-82.